Kate Haviland will succeed Jeff Albers as CEO of Blueprint Medicines Corp., effective April 4, 2022. At that time, Albers will transition from his current role as chairman, president, and CEO to executive chairman of the board of directors. Haviland will transition from her current role as chief operating officer to president and CEO. In addition, Haviland will be appointed to serve on the company’s board of directors.
Mind Medicine Inc., a leading biotech company developing psychedelic-inspired therapies, appointed Robert Barrow as chief executive officer and as a member of the board of directors.
Robert Paul, M.D., Ph.D., joined Nine Square Therapeutics as the biotechnology company’s CEO.
Vivera Pharmaceuticals appointed Donald D’Ambrosio as the company’s chief financial officer.
Patrick Horn, M.D., Ph.D., became chief medical officer of HemoShear Therapeutics effective January 1, 2022.
Dr. James P. Tursi became executive VP, Global Research & Development at Endo effective January 18, 2022.
Richard John Daly was appointed president of CARsgen Therapeutics Corp., a subsidiary of CARsgen Therapeutics Holdings Ltd. in the United States.
Market research patient recruitment firm Rare Patient Voice LLC started off 2022 by reaching a milestone and announcing various staff changes.
Amid the turmoil of the recurring waves of the pandemic, pharma marketers are shifting their focus to new and innovative solutions to engage healthcare professionals, which has led to acceleration of programmatic messaging technologies in the sector.
The total amount of data created, captured, copied, and consumed globally in 2010, at the dawn of the smartphone and social media era, was two zettabytes. So say the analysts at Statista. The total amount of data created, captured, copied, and consumed globally in 2020? 64.2 zettabytes. Projected for 2025? 181 zettabytes.
